About Hydroxychloroquine Sulfate API
Therapeutic Category抗感染
CAS Number
747-36-4
API Technology
合成
Dose Form
口服固体制剂
Dr Reddy's Development Status
可用的
Available Regulatory Filing
USDMF
Mechanism of Action
Malaria - The precise mechanism by which hydroxychloroquine exhibits activity against Plasmodium is not known. Hydroxychloroquine, like chloroquine, is a weak base and may exert its effect by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA.
Rheumatoid Arthritis and Systemic Lupus Erythematosus - The mechanisms underlying the anti-inflammatory and immunomodulatory effects of PLAQUENIL are unknown.
Indication
PLAQUENIL is indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax.
PLAQUENIL is indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported.
PLAQUENIL is indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults.
PLAQUENIL is indicated for the treatment of acute and chronic rheumatoid arthritis in adults.
Related APIs
盐酸左氧氟沙星
抗感染
氯菊酯
抗感染
盐酸特比萘芬
抗感染
盐酸环丙沙星
抗感染
泊沙康唑
抗感染
加替沙星无水合物
抗感染
盐酸莫西沙星无水合物
抗感染
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。